Cyclopamine

Name: Cyclopamine
Brand: Selleck Chemicals
SKU: S1146
Rating: 5 (102 reviews)

For research use only.

Catalog No.S1146 Synonyms: 11-deoxojervine

102 publications

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Selleck's Cyclopamine has been cited by 102 publications

Nature, 2021, 10.1038/s41586-021-03703-z

PubMed: 34234347 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14325

PubMed: 25938716 ( click the link to review the publication )

Neuron, 2021, S0896-6273(21)00506-7

PubMed: 34407390 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(29)e2101783118

PubMed: 34230098 ( click the link to review the publication )

Cancer Res, 2021, canres.0198.2021

PubMed: 34167949 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)418

PubMed: 33499351 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):459

PubMed: 33966040 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):495

PubMed: 33993198 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:675486

PubMed: 34164397 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Sci Rep, 2021, 11(1):16243

PubMed: 34376787 ( click the link to review the publication )

Cancer Med, 2021, 10.1002/cam4.4018

PubMed: 34076346 ( click the link to review the publication )

Molecules, 2021, 26(9)2607

PubMed: 33946996 ( click the link to review the publication )

Oncol Lett, 2021, 21(4):295

PubMed: 33732371 ( click the link to review the publication )

Biology (Basel), 2021, 10(8)767

PubMed: 34439999 ( click the link to review the publication )

Can J Physiol Pharmacol, 2021, 10.1139/cjpp-2020-0588

PubMed: 33617370 ( click the link to review the publication )

J Orthop Surg Res, 2021, 16(1):160

PubMed: 33637095 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2021, 62(2):33

PubMed: 33616621 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Nat Commun, 2020, 11(1):44

PubMed: 31896750 ( click the link to review the publication )

Cell Rep, 2020, 21;31(3):107521

PubMed: 32320667 ( click the link to review the publication )

Int J Cancer, 2020, 7

PubMed: 32383186 ( click the link to review the publication )

Stem Cell Reports, 2020, S2213-6711(20)30192-2

PubMed: 32589876 ( click the link to review the publication )

J Clin Endocrinol Metab, 2020, dgaa656

PubMed: 32936899 ( click the link to review the publication )
Stem Cell Res Ther, 2020, 11(1):488

PubMed: 33198821 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 20;2020:1868764

PubMed: 32377291 ( click the link to review the publication )

Proc Biol Sci, 2020, 287(1935):20192939

PubMed: 32933441 ( click the link to review the publication )

Chemosphere, 2020, 6;254:126709

PubMed: 32348926 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6410

PubMed: 32899202 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.2873

PubMed: 32030915 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2610-2620

PubMed: 33125122 ( click the link to review the publication )

Neural Plast, 2020, 2020:8815195

PubMed: 32802036 ( click the link to review the publication )

Front Pharmacol, 2020, 11:204

PubMed: 32194421 ( click the link to review the publication )

Dev Cell, 2019, 51(6):665-674.e6

PubMed: 31813796 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3134-3152

PubMed: 31371388 ( click the link to review the publication )

Elife, 2019, 8e50208

PubMed: 31482846 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31658643 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(6):896-911

PubMed: 30445456 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2058-2066

PubMed: 30317648 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(8)E1991

PubMed: 31018557 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5386-5395

PubMed: 30367510 ( click the link to review the publication )

J Cell Biochem, 2019, 120(11):18979-18994

PubMed: 31245876 ( click the link to review the publication )

Exp Cell Res, 2019, 385(2):111671

PubMed: 31634481 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2019, 124(6):660-669

PubMed: 30548093 ( click the link to review the publication )

Hepatobiliary Pancreat Dis Int, 2019, 18(1):38-47

PubMed: 30243878 ( click the link to review the publication )
Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Neuron, 2018, 97(6):1235-1243

PubMed: 29526553 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):269-289

PubMed: 29263200 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30014845 ( click the link to review the publication )

Lab Chip, 2018, 18(20):3184-3195

PubMed: 30204194 ( click the link to review the publication )

Exp Cell Res, 2018, 366(1):63-70

PubMed: 29548749 ( click the link to review the publication )

Mol Pain, 2018, 14:1744806918767560

PubMed: 29607715 ( click the link to review the publication )

Biol Reprod, 2018, 98(4):480-490

PubMed: 29329377 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):21-30

PubMed: 29115520 ( click the link to review the publication )

Cell Transplant, 2018, 27(3):393-406

PubMed: 29749250 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):995-1003

PubMed: 30106753 ( click the link to review the publication )

Int J Clin Exp Pathol, 2018, 11(5):2920-2930

PubMed: 31938417 ( click the link to review the publication )

Nat Commun, 2017, 8:14382

PubMed: 28176763 ( click the link to review the publication )

PLoS Genet, 2017, 13(8):e1006951

PubMed: 28797033 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Front Immunol, 2017, 9:2847

PubMed: 30568656 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 44(5):1856-1868

PubMed: 29237157 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):568-578

PubMed: 27709831 ( click the link to review the publication )

Exp Cell Res, 2017, 357(1):79-87

PubMed: 28461158 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 89:147-156

PubMed: 28624529 ( click the link to review the publication )

Mol Immunol, 2017, 92:68-75

PubMed: 29054053 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5605-5619

PubMed: 29200875 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42495-42509

PubMed: 28477008 ( click the link to review the publication )
Dev Cell, 2016, 39(2):239-253

PubMed: 27720610 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):682-94

PubMed: 27113760 ( click the link to review the publication )

J Med Chem, 2016, 59(24):11050-11068

PubMed: 27736063 ( click the link to review the publication )

Cell Biosci, 2016, 10.1186/s13578-016-0104-8

PubMed: 27313840 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Development, 2015, 142(15):2610-22

PubMed: 26116667 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2569-89

PubMed: 26609469 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Int J Mol Med, 2015, 35(6):1641-50

PubMed: 25872645 ( click the link to review the publication )

Insect Sci, 2015, 22(5):587-96

PubMed: 25154865 ( click the link to review the publication )

Data Brief, 2015, 4:22-31

PubMed: 26217756 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(5):816-828

PubMed: 26527387 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):544-59

PubMed: 24553082 ( click the link to review the publication )

Eur J Pharmacol, 2014, 10.1016/j.ejphar.2014.01.074

PubMed: 24534491 ( click the link to review the publication )

Mol Cell Biochem, 2014, 396(1-2):257-68

PubMed: 25064451 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbadis.2014.10.001

PubMed: 25305367 ( click the link to review the publication )

Insect Sci, 2014, 10.1111/1744-7917

PubMed: 25154865 ( click the link to review the publication )

Dev Biol, 2013, 381(2):312-23

PubMed: 23872235 ( click the link to review the publication )

Dev Cell, 2013, 25(2):169-81

PubMed: 23602386 ( click the link to review the publication )

Mol Cancer, 2013, 12:66

PubMed: 23786654 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 5;32(1):7

PubMed: 23379358 ( click the link to review the publication )

Toxicol Lett, 2013, 225(2):318-324

PubMed: 24388991 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )
Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Neuro Oncol, 2012, 14(12):1441-51

PubMed: 23104476 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2262-74

PubMed: 22396494 ( click the link to review the publication )

Cancer Lett, 2012, 322(2):169-76

PubMed: 22450749 ( click the link to review the publication )

Exp Hematol, 2012, 40(5):418-27

PubMed: 22240607 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Targets

Smoothened ^[1]
(TM3Hh12 cells)

46 nM

In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [³H]Hh-Ag binding assay with an IC50 of 280 nM. ^[1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. ^[2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMO^high Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMO^low cell line. ^[3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
OS-RC-2	NWrKSIhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF\4W3NKSzVyPUWuPFY3PiEQvF2=	NUnGXHNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
DOHH-2	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVnJR\|UxRTlwM{W2PFkh\|ryP	NHHwR\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
no-10	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXrJR\|UxRTlwOUCzPUDPxE1?	MkP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LS-513	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3\VUGlEPTB;MUGuN\|U1PyEQvF2=	MmXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ALL-PO	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF;CcWVKSzVyPUGxMlc4OzRizszN	NGLzW289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
8-MG-BA	M4HLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGDHe2pKSzVyPUGzMlEyOjNizszN	NUf2Wpc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RPMI-8402	M1:yRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3HKZ2lEPTB;MUWuPFU{PyEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
EoL-1-cell	NE\lPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIPVOZpKSzVyPUG4MlU6PDhizszN	MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NALM-6	M1rYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnL3TWM2OD1zOT6wNVY4KM7:TR?=	NInNZ249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
DEL	NI\IXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUK4SHp[UUN3ME2yNE4yPDdzIN88US=>	MnrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SR	NUG3bY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWq0dFJuUUN3ME2yN{43PzF3IN88US=>	NGfvWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
697	M4HOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlO3TWM2OD1{Nj62NVU2KM7:TR?=	Mki2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
COLO-829	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYrOfXljUUN3ME2yOk45PDh\|IN88US=>	NWTDbGhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
EVSA-T	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2fBe2lEPTB;MkeuOVU3OSEQvF2=	NIDLe2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ATN-1	M3m2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYfoVIhDUUN3ME2zNU4zOzJ7IN88US=>	M3Xr[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
L-363	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1HYfWlEPTB;M{GuO\|Q3OSEQvF2=	M1jzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LAMA-84	NH[y[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYG4clA{UUN3ME2zNk42OjFzIN88US=>	NXmzNVZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NOS-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2DMUWlEPTB;M{SuNlk2PiEQvF2=	MoSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BB30-HNC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn\nTWM2OD1\|ND6zN\|A3KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BC-1	M3rOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXTJbo1ZUUN3ME2zO{46PzR4IN88US=>	MmXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
IST-SL2	M4CzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2fi[mlEPTB;M{iuNlI1KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
D-392MG	NWLMSpBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXjJR\|UxRTRyLkKyNVUh\|ryP	NEe1Xlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
no-11	NVfmR4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFzMcFBKSzVyPUSwMlU2OjFizszN	MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LC4-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF7jZ5VKSzVyPUSwMlg4OTZizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
A388	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2HDVGlEPTB;NEKuOVg1QCEQvF2=	M4TkXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	NE\BSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXK1ZpBRUUN3ME20Nk44ODd2IN88US=>	MmmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
CESS	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUnJR\|UxRTR2LkKyN\|Ih\|ryP	MmDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
RS4-11	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlzVTWM2OD12OT6wPVM5KM7:TR?=	M1m2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MS-1	M4G2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnroTWM2OD13MD65N\|UyKM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
CTV-1	NGO1WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFPjR2hKSzVyPUWxMlA4PCEQvF2=	M1LXPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
D-502MG	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn;kTWM2OD13MT62NlcyKM7:TR?=	MlznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ML-2	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{TZO2lEPTB;NUKuPVE6PSEQvF2=	Mn7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NETuSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3TvXWlEPTB;NUOuN\|kzOyEQvF2=	M1XoN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LOXIMVI	NFfVcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4nRW2lEPTB;NUOuOVg5PCEQvF2=	MnjJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
DJM-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWHaSmROUUN3ME21Ok4{OzlzIN88US=>	NF;vdFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GI-1	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3m1T2lEPTB;NU[uOlE1QSEQvF2=	NVfNbIJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
IST-MES1	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXqxeVkzUUN3ME22NE42PDl\|IN88US=>	NYDDeXpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MV-4-11	M2LNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVqx[HplUUN3ME22NE43PTN6IN88US=>	Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
OVCAR-4	NHXQeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWrJR\|UxRTZ\|LkW2OVch\|ryP	NEjYTVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KE-37	NYLQNFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmTzTWM2OD14Nj6yOlY5KM7:TR?=	M3fM[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
D-542MG	NXnSUm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVTJR\|UxRTZ6LkSxN\|Uh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	M4nYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWXhfHRxUUN3ME23Nk45PDRzIN88US=>	NVHqdoRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MRK-nu-1	Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWizfpRFUUN3ME23N{41PzB3IN88US=>	NFPrO3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-247MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1HEdGlEPTB;N{OuOVQ1OiEQvF2=	MmHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
OCI-AML2	NUfMeYlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnHrTWM2OD15Nj65N\|Y6KM7:TR?=	NVfUNWNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LP-1	NWnjXWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NInHdVhKSzVyPUiyMlg4OzFizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HCC1599	NVfsS4poT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV;JR\|UxRTh2LkK4N\|ch\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-45	NX3CSlRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV7wN\|VWUUN3ME24OE43QTl{IN88US=>	NFPvdmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BE-13	M2npZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYLJR\|UxRTl7LkC0O\|ch\|ryP	M{jMUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
GCIY	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmXMTWM2OD17OT6wPVU1KM7:TR?=	NFLKNHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BV-173	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHy4Wm1KSzVyPUGwNE4{OjVizszN	Mk\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnTUTWM2OD1zMECuO\|g6KM7:TR?=	Mke5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KS-1	MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4W1fmlEPTB;MUCxMlY{QSEQvF2=	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MOLT-16	Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVPZenA1UUN3ME2xNFQvQTh4IN88US=>	NIXmW\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H1770	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmPuTWM2OD1zMEiuO\|g1KM7:TR?=	NGriUng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H82	NILWSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NF\Qbo1KSzVyPUGxNE46PzZizszN	NFO5ZYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCCIT	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWmyVXI3UUN3ME2xNVIvPTJ7IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KALS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYHITpBuUUN3ME2xNVUvQTRzIN88US=>	M1LWUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB2241-RCC	NWTz[HdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlHsTWM2OD1zMU[uOlc6KM7:TR?=	M3XoOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HH	NHfpcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mk\6TWM2OD1zMUeuN\|k2KM7:TR?=	MnjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEfBeVBKSzVyPUGxPE41QDhizszN	NViwRnJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
EB-3	M1KwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{TSXGlEPTB;MUKzMlA6PCEQvF2=	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BL-70	M2HTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIHP[ZRKSzVyPUGyN{4yOjdizszN	MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
K-562	M4ryb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHvpOpNKSzVyPUGyOk4zPDVizszN	M2LiNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HT-144	NVPqN5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3LqfGlEPTB;MUOzMlE3PCEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
PF-382	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{fVeWlEPTB;MUO0MlM3OSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
RPMI-8226	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUnJR\|UxRTF\|NT6wOFUh\|ryP	NUHzT\|hURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1355	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVzJR\|UxRTF\|NT61PFch\|ryP	NF60S5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LXF-289	M1TIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmHITWM2OD1zM{muO\|gyKM7:TR?=	M2TwZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCI-H69	MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1fsWmlEPTB;MUSyMlk{OiEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
SK-MEL-1	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnjpTWM2OD1zNEeuNVMh\|ryP	MkDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KARPAS-299	NIHMT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxRTF2OT6xNkDPxE1?	NXXMWJBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
GB-1	MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVPqeXMzUUN3ME2xOFkvOzJ{IN88US=>	NXv0ZmF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
CMK	M3XrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHnhfJFKSzVyPUG0PU42OTVizszN	MkCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MPP-89	M2jjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{D5eWlEPTB;MUW2MlA{PSEQvF2=	NUj5[5JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KU812	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXu1ZmhtUUN3ME2xOlEvQTB{IN88US=>	M3XGdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
REH	M2S0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnnYTWM2OD1zNkKuNVI2KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NEC8	NXP3TJNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYXpZlJFUUN3ME2xOlUvODJ4IN88US=>	MmXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KP-N-YS	MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmLqTWM2OD1zNkiuN\|k2KM7:TR?=	NHq1SXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn62TWM2OD1zNkmuPVE2KM7:TR?=	MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
Becker	NXPpdIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF3rbIpKSzVyPUG3OE4yQCEQvF2=	NIjkVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LB647-SCLC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1:0d2lEPTB;MUe1Mlg1PSEQvF2=	MkTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LU-139	M3\JSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHfFbJJKSzVyPUG3PE4xOTlizszN	MmLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	M2LIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2fEU2lEPTB;MUe5MlY1PiEQvF2=	M{nMNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCI-H1395	M1r6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYLJR\|UxRTF5OT65PVYh\|ryP	NXq5Nmt5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NOMO-1	NYPmZoJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUHJR\|UxRTF6Mj64OUDPxE1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
GI-ME-N	M{\FU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHfSOo9KSzVyPUG4O{46PjlizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KMS-12-PE	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlrJTWM2OD1zOEmuNlc{KM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
Daudi	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEHVcnZKSzVyPUG5NU4yOjhizszN	M1\XS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB996-RCC	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnHVTWM2OD1zOUGuOlk6KM7:TR?=	MlvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H2107	NU\qTVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXLaOpJZUUN3ME2xPVMvPzN7IN88US=>	M1exO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SK-PN-DW	NGHtXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2L5dGlEPTB;MUm0MlcyQSEQvF2=	NXTLRlVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MC-CAR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYHI[ZlHUUN3ME2yNFIvOjV\|IN88US=>	M2XU[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SNB75	M4LSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NES1OItKSzVyPUKyNU46PCEQvF2=	NXfBdW1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ES4	M2DIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVLJR\|UxRTJ{Mz63PFMh\|ryP	M4e2dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KARPAS-422	M13sfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3fnPWlEPTB;MkK4MlM2OiEQvF2=	NXHHUmYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1648	NU\UT2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MY\JR\|UxRTJ{OT60PFkh\|ryP	MnP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ES6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1K3N2lEPTB;MkO5MlQ{KM7:TR?=	NVuwZpA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KNS-81-FD	NHi1VWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NInkVoxKSzVyPUK0NU4yQTdizszN	M1:5[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
JAR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEXZd2FKSzVyPUK1Ok4zOjVizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NB1	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV;mVVZ3UUN3ME2yOlAvPTF4IN88US=>	NUXtV21uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
D-336MG	M3nubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlXCTWM2OD1{NkCuOlk5KM7:TR?=	Mn34QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BC-3	NIrzPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M37JTWlEPTB;Mk[1MlE4QCEQvF2=	Mn\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HCC2218	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF30XoJKSzVyPUK2Ok41OTVizszN	NFnGTW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
TE-9	MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnHWTWM2OD1{Nk[uOlI4KM7:TR?=	M37xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB1047-RCC	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYPJR\|UxRTJ4Nj63OVMh\|ryP	NX3HRWltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
CTB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NImzdI5KSzVyPUK2PU46PzNizszN	M{\DbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NB7	NF\KR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVO2O2hSUUN3ME2yO\|Eh\|ryP	NWLVUnVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ST486	NXrj[4pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2HuZWlEPTB;Mke3MlQyOiEQvF2=	NYrOT2s6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HCC1187	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmHDTWM2OD1{OEKuPFEyKM7:TR?=	NWXYWnJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-SNU-16	NIjaVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NED0epZKSzVyPUK4OE4zPDhizszN	Mk\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
COR-L279	NXq5enllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV33PXdVUUN3ME2yPVEvPTh2IN88US=>	NV;pfZl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ES8	NYPYTJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn;pTWM2OD1{OUSuNVgzKM7:TR?=	Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U-698-M	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUHkRYxuUUN3ME2yPVgvOjR\|IN88US=>	NXzPO45iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HEL	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MU\JR\|UxRTNyOT6xOFkh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KINGS-1	NX21UG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml\lTWM2OD1\|MUCuOlc1KM7:TR?=	MlrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KY821	NEf3T41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkLITWM2OD1\|M{[uOVk2KM7:TR?=	M170XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MZ1-PC	NWTo[pZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGHPclRKSzVyPUO0OU43OThizszN	MonIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LS-411N	NE[xUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml7pTWM2OD1\|NUSuOlYh\|ryP	M3PycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SIG-M5	NWXCNVJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3zoVWlEPTB;M{W5Mlc5OiEQvF2=	M2HXTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HT	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1;WV2lEPTB;M{[3MlcyOSEQvF2=	NYnJbnNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HC-1	NXu0ZppvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGntZpdKSzVyPUO2O{44QDdizszN	Ml3hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1694	M1HGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUfJR\|UxRTN5Mj65N\|Qh\|ryP	NEP4V4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BB65-RCC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlzvTWM2OD1\|N{[uNlQ2KM7:TR?=	MojWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HAL-01	M1\wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn\tTWM2OD1\|N{muPFM5KM7:TR?=	M1TrUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ARH-77	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NU\SelVVUUN3ME2zPVQvODB6IN88US=>	NEXk[Ic9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MZ7-mel	NHrwTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mmq4TWM2OD1\|OUeuNlM{KM7:TR?=	NYXNNlVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SIMA	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUnhRYx6UUN3ME20NFMvQTN\|IN88US=>	NFrFRoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
DG-75	NUflc41wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVTJR\|UxRTRzNT62PVgh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HUTU-80	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnPSTWM2OD12MUmuNVg2KM7:TR?=	NIL4V4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KNS-42	M2\GcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkXwTWM2OD12MkWuPFE2KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
SH-4	NULGeHVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG\UNXNKSzVyPUSyO{42PjVizszN	M2TjRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
L-540	M{DxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV;rNY1EUUN3ME20N\|EvODNzIN88US=>	M{T3SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NB10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXPWWpg4UUN3ME20OFEvOjN2IN88US=>	NFrER4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ES1	NYrQ[3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWjJR\|UxRTR3Mj63OVMh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KMOE-2	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2\1S2lEPTB;NEW2MlcyOSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MC116	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2S1cGlEPTB;NEW4MlEyPiEQvF2=	NWH6TnNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RCC10RGB	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH\JTXhKSzVyPUS2NE4xODVizszN	M{TLfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
RL95-2	M2DPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWfJR\|UxRTR4MD6yN\|ch\|ryP	MkX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
Raji	NVnBOY0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnzZTWM2OD12NkiuNVQ{KM7:TR?=	M3TaTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
CAS-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFvyZXRKSzVyPUS3Nk4xPzNizszN	NIixOIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Calu-6	M2r5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEjseFJKSzVyPUS3OU4zPjVizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KG-1	NYHMXnRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1XsOmlEPTB;NEe4MlQ1KM7:TR?=	MmrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LB771-HNC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVfJR\|UxRTR6Mj6yN\|Ih\|ryP	M1u5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ACN	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYHJR\|UxRTR7Mz61PVkh\|ryP	NGDYO2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KM12	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUfCcWhNUUN3ME20PVYvPTh7IN88US=>	NFKyfJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
U2OS	NEH2S\|FHfW6ldHnvckBie3OjeR?=			NW\ob\|V1SmmwZHnu[{Bi\m[rbnn0fUB1dyC5aXzkJJR6eGViU33vJIV5eHKnc4Pl[EBqdiCXMl;TJINmdGy\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFvkJF0hOC5yMUK0JO69VS5?	Mn3zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
U2OS	MY\GeY5kfGmxbjDhd5NigQ>?		MW[yJIhzew>?	MWnEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32ge4lt\CC2eYDlJHNudyCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvODF{NzFOwG0v	NGe3bGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
TM3	NXHVeo5zTnWwY4Tpc44h[XO\|YYm=		MXS0PEBpenN?	MUHJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKFSPMzDj[YxteyCkZXHybY5oKHCWQT24fGdtcS2OdXOgdoVxd3K2ZYKgZ49ve3S{dXP0JIF{e2W\|c3XkJIF{KHS{YX7zZ5JqeHSrb37hcEBud2S3bHH0bY9vKG:oIFfsbUBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBie3OjeTygTWM2OCB;IECuNFQ3KM7:TT6=	MmHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyOUG1OVkoRjF7MEmxOVU6RC:jPh?=
HCC827	NYKyeFBITnWwY4Tpc44h[XO\|YYm=			MkLRSIl{eGyjY3Xt[Y51KG:oIGuzTH0u[3mlbH;wZY1qdmViZoLvcUBUVU9iVkSwOG0hdXW2YX70JIlvKGenZnn0bY5q[iC{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFvpJF0hOC5yNUGg{txONg>?	NFXpS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe4O\|E2Pid-Mki3PFcyPTZ:L3G+
HEK293	NYHhfI5VTnWwY4Tpc44h[XO\|YYm=		MUKyJIhzew>?	MW\EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWyjYnXscIVlKGO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHluIFnDOVAhRSByLkC2OEDPxE1w	NFe3PYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFU2OSd-MkKyOlg2PTF:L3G+
Shh Light2	Mm\KSpVv[3Srb36gZZN{[Xl?		M{LQVVMxKGi{cx?=	M2XieGlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHOxbnnjJIhm\GenaH;nMYlv\HWlZXSgS2xKOS2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhdWWjc4Xy[YQh[W[2ZYKgN\|AhcHK\|IHL5JIR2[WxibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xPzRzIN88UU4>	MmHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NkezO\|EoRjJ5NU[3N\|cyRC:jPh?=
U2OS	M1\xZmZ2dmO2aX;uJIF{e2G7			MVjCbY5lcW6pIHHm[olvcXS7IITvJHNudyCGNEezTEBufXSjboSg[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3SgQUAxNjFzNjFOwG0v	M1fKNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[zOVIzLz5{M{C2N\|UzOjxxYU6=
DaOY	NYfETmxNTnWwY4Tpc44h[XO\|YYm=		NFfWd4I1QCCqcoO=	NYDGOohMUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hcHWvYX6gSIFQYSClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC5zNjFOwG0v	NF;BcZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
U2OS	MWXGeY5kfGmxbjDhd5NigQ>?		M1nvZVIhcHK\|	NF3Z[YxFcXOybHHj[Y1mdnRib3[gX\|NJZWO7Y3zvdIFucW6nIH\yc40hW22xIFS0O\|NJKG23dHHueEBmgHC{ZYPz[YQhcW5iVULPV{Bk\WyuczDh[pRmeiB{IHjyd{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcSB;IECuNlMzKM7:TT6=	M1nhZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[zOVIzLz5{M{C2N\|UzOjxxYU6=
CHO	M4izXmZ2dmO2aX;uJIF{e2G7			MVHBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHNudyC{ZXPldJRweiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KFt\|SG3IbE1C\yCkaX7kbY5oKGG\|c3H5MEBKSzVyIE2gNE4zQCEQvF2u	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7MUW1PUc,OTlyOUG1OVk9N2F-
Shh Light2	MkTHSpVv[3Srb36gZZN{[Xl?		M3jheVQxKGi{cx?=	MV\Jcohq[mm2aX;uJI9nKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYX\0[ZIhPDBiaILzJIJ6KEeuaT3k[ZBmdmSnboSgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5\|IN88UU4>	NF3p[pI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW5Nlc5QCd-MkG1PVI4QDh:L3G+
Shh-light2	M2\YS2Z2dmO2aX;uJIF{e2G7			MVrJcohq[mm2aX;uJI9nKFOvbz3t[YRq[XSnZDDIbEB{cWewYXzpcochcW5iaIXtZY4hW2iqLXzp[4h1OiClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlMh\|ryPLh?=	Ml:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1OVEoRjJ{Mk[4OVUyRC:jPh?=
M210B4	MXjGeY5kfGmxbjDhd5NigQ>?		NVXMRZI1OjRiaILz	MV3Jcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCPMkGwRlQh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhWHSlaDDtVm5CKGW6cILld5Nqd25iYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvPDNizszNMi=>	MnPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
Shh-Light 2	NGm3U3VHfW6ldHnvckBie3OjeR?=		MlvtNkBl[Xm\|	MV\BcpRi\2:waYP0JIFkfGm4aYT5JIF1KFOvbzDpckBud3W\|ZTDTbIguVGmpaISgNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcTFvcnXwc5J1\XJiYXP0bZZqfHliYX\0[ZIhOiCmYYnzJIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIH3leIhw\CxiSVO1NEA:KDBwNEi0JO69VS5?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
Shh Light2	NVnFcFFQTnWwY4Tpc44h[XO\|YYm=			NWnJSIs1UW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqIFzp[4h1OiClZXzsd{BjgSCJTFmtdoV{eG:wc3n2[UBncXKnZnz5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwNTFOwG0v	M17yclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C5NFgxLz5zOUOwPVA5ODxxYU6=
C3H10T1/2	NUXaVZpiTnWwY4Tpc44h[XO\|YYm=			NH\WcmtKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygV2hJKGGldHn2ZZRm\CCyYYToe4F6KGmwIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCVQVetbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvckBjgSCjbHvhcIlv\SCyaH;zdIhifGG\|ZTDhd5NigSxiSVO1NEA:KDBwNjFOwG0v	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV7Mke4PEc,OjF3OUK3PFg9N2F-
C3H10T1/2	NITQeYhHfW6ldHnvckBie3OjeR?=		NHnReWw3KGi{cx?=	NXvLeI5OUW6qaXLpeIlwdiCxZjDTRWcucW6mdXPl[EBlcW[oZYLlcpRq[XSrb36gc4YhdW:3c3WgcYV{\W6laIntZYwheGy3cnnwc5RmdnRiQ{PINVBVOS9{IHPlcIx{KHSxIHHsb4FtcW6nIIDoc5NxcGG2YYPlJJBwe2m2aY\lJI9me2WxYnzhd5R{KGGodHXyJFYhcHK\|LDDJR\|UxKD1iMD62NkDPxE1w	M4G2RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
ASZ001	MYHGeY5kfGmxbjDhd5NigQ>?		NG\QV281QCCqcoO=	NUS5[YdGUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgRXNbODBzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIFfsbVEhdVKQQTDlfJBz\XO\|aX;uJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNuIFnDOVAhRSByLk[2JO69VS5?	MnW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
M210B4	NHftb21HfW6ldHnvckBie3OjeR?=		MkL3NlQhcHK\|	M3H6N2lvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC56IN88UU4>	NX;kOGZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
medulloblastoma cells	M3LufGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NVfhNI1SSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDt[YR2dGyxYnzhd5RwdWFiY3XscJMhcGG{Yn;ybY5oKGindHXyc5p6\2:3czDweINpOSCpZX7lJIJ6KE2WVDDhd5NigSxiRVO1NEA:KDFizszNMi=>	M3vQXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG3OlMyLz5zN{SxO\|Y{OTxxYU6=
CHO	M33pTGZ2dmO2aX;uJIF{e2G7			MV\BcpRi\2:waYP0JIFkfGm4aYT5JIF1KG2xdYPlJHNudyC{ZXPldJRweiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KFt\|SG3IbE1C\yCkaX7kbY5oKGG\|c3H5MEBKSzVyIE2gNU4zKM7:TT6=	NWnB[lJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPVE2PTlpPkG5NFkyPTV7PD;hQi=>
Shh-Light2	MkXxSpVv[3Srb36gZZN{[Xl?		MYm0PEBpenN?	MV;Jcohq[mm2aX;uJI9nKFOKSDDpckBud3W\|ZTDTbIguVGmpaISyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCJbHmxJJJmeG:{dHXyJIdmdmViYYPzZZkhcW5icILld4Vv[2Vib3[gV2FINCCLQ{WwJF0hOS5\|MUKg{txONg>?	NVvHb4w2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1OFE1QTBpPkG5OVQyPDlyPD;hQi=>
MEF	MXfGeY5kfGmxbjDhd5NigQ>?			NYTxUYJRUW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhWHSlaD3k[YZq[2mnboSgUWVHKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV4hpNWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHluIFnDOVAhRSBzLkWg{txONg>?	MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{S1OFEoRjJ\|MEe0OVQyRC:jPh?=
MEF	NX;UV3c1TnWwY4Tpc44h[XO\|YYm=		NWfYNlF[OzBiaILz	MUHJcohq[mm2aX;uJI9nKFOvbzDpckBud3W\|ZTDQeINpNWSnZnnjbYVvfCCPRV[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVaHitbY5lfWOnZDDHcIkuemW\|cH;ud4l3\SCkZYTh[4Ft[WO2b4Pp[IF{\SCjY4Tpeol1gSCjZoTldkA{OCCqcoOgZpkhSmW2YVfMc{Bie3OjeTygTWM2OCB;IEGuPUDPxE1w	M1\UelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe0OVQyLz5{M{C3OFU1OTxxYU6=
neural precursor cells	MmDPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NXLkbYx[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDu[ZVz[WxicILlZ5Vze2:{IHPlcIx{KGK7IHPvcI9vgSCob4LtZZRqd25iYYPzZZktKEWFNUCgQUAyOy52NDFOwG0v	NYDISpd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVc3OzFpPkG3OFE4PjNzPD;hQi=>
U87	NYS3d4VzS3m2b4TvfIlkcXS7IHHzd4F6			M1LKeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU5PyClZXzsd{Bie3Onc4Pl[EBieyC4aXHibYxqfHliaX6gdJJme2WwY3Wgc4Yh[mW2YTDncJVkfXKxbnnkZZNmNCCLQ{WwJF0hOTVwNTFOwG0v	MkW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMU[5NFQoRjJyMUG2PVA1RC:jPh?=
U87MG	MnTIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2TpZ\|czKGi{cx?=	NV;RTYhySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNlIvPSEQvF2u	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ{Nk[1O{c,OjJ{Mk[2OVc9N2F-
A549	NFz2SYtCdnSrY3HuZ4VzKGG\|c3H5			NV63eXFpSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iNEmg{txONg>?	NEPic5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEKyNVg4Oid-MUiyNlE5PzJ:L3G+
DU145	MmHmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEjvPVk2KHWP	NHrDSnY6PiCqcoO=	MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BifCB3IIXNJIFnfGW{IEm2JIhzew>?	MlvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEmxNlUoRjF6MkS5NVI2RC:jPh?=
DU145	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M33hOFExKHWP	M4LPcFk3KGi{cx?=	M1y3WGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGG2IEGwJJVOKGGodHXyJFk3KGi{cx?=	MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEmxNlUoRjF6MkS5NVI2RC:jPh?=
HEK293	MYHGeY5kfGmxbjDhd5NigQ>?			MU\Jcohq[mm2aX;uJI9nKGKndHGg[4Ft[WO2b4Pp[IF{\SCrbjDISWszQTNiY3XscJM>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
22Rv	NGHvNYpHfW6ldHnvckBie3OjeR?=			M4LBUXJm\HWldHnvckBw\iCneIDy[ZN{cW:wIH;mJHBVS0hibWLORUBqdiCqdX3hckAzOlK4IHPlcIx{	NXzhR4dERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
PANC1	MmjPSpVv[3Srb36gZZN{[Xl?	MXqwMlIhfU1?	MWCyOEBpenN?	M4j3Z2lvcGmkaYTpc44hd2ZiSHivS2xKOS2vZXTpZZRm\CCSVFPIJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDQRW5EOSClZXzsd{BifCByLkKgeW0h[W[2ZYKgNlQhcHK\|IHL5JHJVNVCFUh?=	NIK2SoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NFE4OCd-MkC0OVAyPzB:L3G+
PANC1	MW\GeY5kfGmxbjDhd5NigQ>?	MX2wMlQhfU1?	NWS0VYR3OjRiaILz	NX3yR25GUW6qaXLpeIlwdiCxZjDIbE9IVElzLX3l[IlifGWmIGDUR2ghdVKQQTDlfJBz\XO\|aX;uJIlvKGi3bXHuJHBCVkNzIHPlcIx{KGG2IECuOEB2VSCjZoTldkAzPCCqcoOgZpkhWlRvUFPS	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR3MEG3NEc,OjB2NUCxO\|A9N2F-
Shh Light2	Mk\6SpVv[3Srb36gZZN{[Xl?	MVe2MlI2KHWP	MnvYN\|AhcHK\|	NFvET2tKdmirYnn0bY9vKG:oIF6tdIFtdWm2b4nsZZRm\CCVaHigbY4hdW:3c3WgV4hpKEyrZ3j0NkBk\WyuczDheEA3NjJ3IIXNJIFnfGW{IEOwJIhzeyCkeTDmbZJm\my7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=>	M3vT[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUWxO\|MyLz5zOUG1NVc{OTxxYU6=
U87MG	NXnPbYtGTnWwY4Tpc44h[XO\|YYm=	NUf1Zo5sOTBidV2=	MmnKOEBpenN?	NH7PSoRKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd36gdoVofWyjdHnvckBw\iCJbHmxJIF1KDFyIIXNJIFnfGW{IESgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>?	NFTRO409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKyOlY2Pyd-MkKyNlY3PTd:L3G+
HEK293	MnvqSpVv[3Srb36gZZN{[Xl?	NEf4fWk2KHWP	MlTHNVAhcHK\|	MX3EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XRiNTD1UUBu\WG\|dYLl[EBi\nSncjCxNEBpenNiYomgSGFRUSC\|dHHpcolv\yCkYYPl[EBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yaXOgZZN{[Xl?	NY[zTow6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3N\|YxPjNpPkK3O\|M3ODZ\|PD;hQi=>
HEK293	NHzNcotHfW6ldHnvckBie3OjeR?=	MYW1JJVO	NV3yV2wzOTBiaILz	M{frRWRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvY4njcI9x[W2rbnWg[pJwdSCqdX3hckBUdW9iZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjdDC1JJVOKG2nYYP1doVlKGGodHXyJFExKGi{czDifUBHSUOVIHHuZYx6e2m\|	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd\|NkC2N{c,Ojd5M{[wOlM9N2F-
C3H10T1/2	M2XJ[2Z2dmO2aX;uJIF{e2G7	M4G1[lU2NjVidH:gOFUxOCCwTR?=		MnGzR49ueGW2aYTpeoUhcW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV2FINWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYYSgOVUvPSC2bzC0OVAxKG6PIHL5JJFRS1JiYX7hcJl{cXN?	M4HxXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe0OVQyLz5{M{C3OFU1OTxxYU6=
U2OS	MljhSpVv[3Srb36gZZN{[Xl?	MmP1OUB2VQ>?	MmrTOkBpenN?	MXLBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGOqaX3ldolkKFOvbzC2N\|MhdXW2YX70JIV5eHKnc4Pl[EBqdiCXMl;TJINmdGy\|IHPv[ZhxemW\|c3nu[{Bj\XSjIHHydoV{fGmwMj3HSnAh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBqdnS{YXPlcIx2dGG{IHLleIEh[XK{ZYP0bY4zNUeIUDDh[4dz\WejdHWg[o9zdWG2aX;uJIF1KDVidV2gZYZ1\XJiNjDodpMh[nliY3;u[o9k[WxibXnjdo9{[2:yeR?=	NV3idlNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Snail / E-cadherin / Slug / Vimentin ; PubMed: 26859575 Oncotarget SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT. Gli1 / TGF-β1 / CXCR4; PubMed: 26137001 Oncol Lett Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h. NF-κB / Cyclin D1 / MMP2 / MMP9; PubMed: 23599805 Oncol Lett Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9.	26859575 26137001 23599805
Immunofluorescence	PCNA / β-catenin; PubMed: 28747625 Sci Rep Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times. Vimentin; PubMed: 24553082 Cancer Biol Ther Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.	28747625 24553082

In vivo

Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. ^[2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMO^low tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Hedgehog cell assay: This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO₂. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO₂. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:^[2]	- Collapse Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116 Concentrations: Dissolved in DMSO, final concentration 3 μM Incubation Time: 4 days Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD₄₉₀) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2). (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells Dosages: 50 mg/kg/day Administration: Subcutaneous injection (Only for Reference)

References

[4] Feldmann G, et al. Cancer Res, 2007, 67(5), 2187-2196.

- Collapse

Solubility (25°C)

In vitro	DMF	10 mg/mL warmed (24.29 mM)
	Ethanol	2 mg/mL warmed (4.85 mM)
	DMSO	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Cyclopamine SDF

Molecular Weight	411.62
Formula	C₂₇H₄₁NO₂
CAS No.	4449-51-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	11-deoxojervine
Smiles	CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo use in mice?
Answer:
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Smoothened Inhibitor in Clinical Trial

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
Newest Smoothened Inhibitor

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened Activator

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

Related Hedgehog/Smoothened Products

Smoothened Agonist (SAG) HCl ^New

Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
SB225002 ^New

SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.
SB-334867 ^New

SB-334867 is a selective orexin-1 (OX1) receptor antagonist.
Vismodegib (GDC-0449)

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
GANT61

GANT61 (NSC 136476) is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation. GANT61 induces apoptosis and activates protective autophagy in LX-2 cells.
Purmorphamine

Purmorphamine (Shh Signaling Antagonist VI), which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM. Purmorphamine can reduce both basal and induced autophagy.
Sonidegib (NVP-LDE225)

Sonidegib (Erismodegib, NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.
Taladegib (LY2940680)

Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.
Glasdegib (PF-04449913)

Glasdegib (PF-04449913) is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Cyclopamine